company background image
DVAX

Dynavax Technologies NasdaqCM:DVAX Stock Report

Last Price

US$17.02

Market Cap

US$2.2b

7D

22.5%

1Y

45.6%

Updated

09 Aug, 2022

Data

Company Financials +
DVAX fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance4/6
Financial Health5/6
Dividends0/6

DVAX Stock Overview

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States.

Dynavax Technologies Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Dynavax Technologies
Historical stock prices
Current Share PriceUS$17.02
52 Week HighUS$21.39
52 Week LowUS$7.26
Beta1.29
1 Month Change14.69%
3 Month Change128.46%
1 Year Change45.60%
3 Year Change384.90%
5 Year Change5.06%
Change since IPO-81.89%

Recent News & Updates

Aug 04

Dynavax up 8% after raising full-year guidance for key adjuvant product, Q2 beats

Dynavax Technologies (NASDAQ:DVAX) is up 8% in after-hours trading after upping its 2022 guidance for revenue of its key product, the vaccine adjuvant CpG 1018. The company now expects 2022 sales of CpG 1018 of $550M-$600M. In May, it was projected at $550M. CpG 1018 brought in $222.6M in Q2, a massive increase from the $39M in Q2 2021. Total revenue of $256.5M was a 386% year-over-year increase. GAAP net income was $32.9 million, 0.26 per share (basic) and 0.22 per share (diluted) in the quarter, compared to GAAP net income of $0.9 million, or $0.01 per share (basic and diluted) the prior-year period. Dynavax (DVAX) beat on the top and bottom lines in the quarter. The company ended Q2 with $518.2M in cash and cash equivalents, compared to ~$546M at Dec. 31, 2021. Seeking Alpha's Quant Rating views Dynavax (DVAX) as a strong buy with high marks for profitability and momentum.

Shareholder Returns

DVAXUS BiotechsUS Market
7D22.5%6.3%0.3%
1Y45.6%-25.9%-13.5%

Return vs Industry: DVAX exceeded the US Biotechs industry which returned -25.9% over the past year.

Return vs Market: DVAX exceeded the US Market which returned -13% over the past year.

Price Volatility

Is DVAX's price volatile compared to industry and market?
DVAX volatility
DVAX Average Weekly Movement12.0%
Biotechs Industry Average Movement12.8%
Market Average Movement7.9%
10% most volatile stocks in US Market17.2%
10% least volatile stocks in US Market3.2%

Stable Share Price: DVAX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: DVAX's weekly volatility (12%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1996311Ryan Spencerhttps://www.dynavax.com

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B.

Dynavax Technologies Fundamentals Summary

How do Dynavax Technologies's earnings and revenue compare to its market cap?
DVAX fundamental statistics
Market CapUS$2.15b
Earnings (TTM)US$228.49m
Revenue (TTM)US$672.60m

9.4x

P/E Ratio

3.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
DVAX income statement (TTM)
RevenueUS$672.60m
Cost of RevenueUS$287.07m
Gross ProfitUS$385.52m
Other ExpensesUS$157.04m
EarningsUS$228.49m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)1.81
Gross Margin57.32%
Net Profit Margin33.97%
Debt/Equity Ratio52.3%

How did DVAX perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is DVAX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for DVAX?

Other financial metrics that can be useful for relative valuation.

DVAX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.8x
Enterprise Value/EBITDA7.1x
PEG Ratio-0.2x

Price to Earnings Ratio vs Peers

How does DVAX's PE Ratio compare to its peers?

DVAX PE Ratio vs Peers
The above table shows the PE ratio for DVAX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average16.1x
RCUS Arcus Biosciences
27.3x26.7%US$1.8b
ALEC Alector
28.8x-25.9%US$1.0b
QURE uniQure
n/a36.9%US$887.2m
RGNX REGENXBIO
16.2x-3.1%US$1.5b
DVAX Dynavax Technologies
9.4x-42.5%US$2.2b

Price-To-Earnings vs Peers: DVAX is good value based on its Price-To-Earnings Ratio (9.4x) compared to the peer average (16.1x).


Price to Earnings Ratio vs Industry

How does DVAX's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Earnings vs Industry: DVAX is good value based on its Price-To-Earnings Ratio (9.4x) compared to the US Biotechs industry average (16.6x)


Price to Earnings Ratio vs Fair Ratio

What is DVAX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DVAX PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio9.4x
Fair PE Ratio13.6x

Price-To-Earnings vs Fair Ratio: DVAX is good value based on its Price-To-Earnings Ratio (9.4x) compared to the estimated Fair Price-To-Earnings Ratio (13.6x).


Share Price vs Fair Value

What is the Fair Price of DVAX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: DVAX ($17.02) is trading below our estimate of fair value ($17.55)

Significantly Below Fair Value: DVAX is trading below fair value, but not by a significant amount.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Dynavax Technologies forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-42.5%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: DVAX's earnings are forecast to decline over the next 3 years (-42.5% per year).

Earnings vs Market: DVAX's earnings are forecast to decline over the next 3 years (-42.5% per year).

High Growth Earnings: DVAX's earnings are forecast to decline over the next 3 years.

Revenue vs Market: DVAX's revenue is expected to decline over the next 3 years (-10.8% per year).

High Growth Revenue: DVAX's revenue is forecast to decline over the next 3 years (-10.8% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if DVAX's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Dynavax Technologies performed over the past 5 years?

Past Performance Score

4/6

Past Performance Score 4/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


39.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: DVAX has high quality earnings.

Growing Profit Margin: DVAX became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: DVAX has become profitable over the past 5 years, growing earnings by 39% per year.

Accelerating Growth: DVAX has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: DVAX has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (40.8%).


Return on Equity

High ROE: DVAX's Return on Equity (55.1%) is considered outstanding.


Discover strong past performing companies

Financial Health

How is Dynavax Technologies's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: DVAX's short term assets ($955.4M) exceed its short term liabilities ($345.2M).

Long Term Liabilities: DVAX's short term assets ($955.4M) exceed its long term liabilities ($255.0M).


Debt to Equity History and Analysis

Debt Level: DVAX has more cash than its total debt.

Reducing Debt: Insufficient data to determine if DVAX's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: DVAX's debt is well covered by operating cash flow (69.2%).

Interest Coverage: DVAX's interest payments on its debt are well covered by EBIT (46.5x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is Dynavax Technologies's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate DVAX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate DVAX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if DVAX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DVAX's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as DVAX has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.5yrs

Average management tenure


CEO

Ryan Spencer (44 yo)

2.67yrs

Tenure

US$4,519,489

Compensation

Mr. Ryan Spencer serves as the Chief Executive Officer and Director of Dynavax Technologies Corp. since December 16, 2019. He had been Co-President and Co-Principal Executive Officer of Dynavax Technologie...


CEO Compensation Analysis

Compensation vs Market: Ryan's total compensation ($USD4.52M) is about average for companies of similar size in the US market ($USD5.45M).

Compensation vs Earnings: Ryan's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: DVAX's management team is considered experienced (2.5 years average tenure).


Board Members

Experienced Board: DVAX's board of directors are considered experienced (4.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.2%.


Top Shareholders

Company Information

Dynavax Technologies Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: Dynavax Technologies Corporation
  • Ticker: DVAX
  • Exchange: NasdaqCM
  • Founded: 1996
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$2.153b
  • Shares outstanding: 126.47m
  • Website: https://www.dynavax.com

Number of Employees


Location

  • Dynavax Technologies Corporation
  • 2100 Powell Street
  • Suite 900
  • EmeryVille
  • California
  • 94608
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/09 00:00
End of Day Share Price2022/08/09 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.